MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab Higher rates of complete skin clearance were...

MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with...